CK 2127107

Drug Profile

CK 2127107

Alternative Names: CK-107; CK-2127107

Latest Information Update: 01 Apr 2017

Price : $50

At a glance

  • Originator Cytokinetics
  • Developer Astellas Pharma; Cytokinetics
  • Class Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Muscular atrophy

Most Recent Events

  • 22 Mar 2017 Interim pharmacodynamics data from a preclinical study in Spinal muscular dystrophy released by Cytokinetics
  • 16 Feb 2017 Astellas plans a phase Ib trial in eldrely patients with limited mobility
  • 16 Feb 2017 Cytokinetics plans a phase II trial in patients with Amyotrophic lateral sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top